<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876210</url>
  </required_header>
  <id_info>
    <org_study_id>PK101_P102</org_study_id>
    <nct_id>NCT03876210</nct_id>
  </id_info>
  <brief_title>Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2x2 Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination or Loose Combination of PK101 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PMG Pharm Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PMG Pharm Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and pharmacokinetics of PK101(fixed-dose
      combination of PK101-001 and PK101-002) with coadministration of the two separate drugs in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Area under the plasma/serum/blood drug concentration-time curve from time zero to the time of the last quantifiable concentration of PK101-002</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Maximum Plasma Concentration of PK101-002</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Time of peak concentration of PK101-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity of PK101-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Terminal half life of PK101-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>Clearance/Bioavailability of PK101-002</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf</measure>
    <time_frame>0(Pre-dose), 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour</time_frame>
    <description>AUCt/AUCinf of PK101-002</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: PK101-001, PK101-002 / Period 2: PK101
Number of subject: 23
Wash out Period: over 7 days (between each period)
Dosage: Once daily, at 2D each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: PK101 / Period 2: PK101-001, P101-002
Number of subject: 23
Wash out Period: over 7 days (between each period)
Dosage: Once daily, at 2D each period</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PK101</intervention_name>
    <description>PK101-001 + PK101-002 (combination)</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PK101-001, PK101-002</intervention_name>
    <description>coadministration</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults ≥ 19 years of age (on the day of screening)

          -  Body weigth ≥50.0kg, 18.5Kg/(m)^2 ≤ (BMI) ≤30.0Kg/(m)^2

          -  No congenital or chronic diseases and no abnormal signs determined by medical
             examinations

          -  Not abnormal or not clinical significant lab values

          -  Understand the requirements of the study and voluntarily consent to participate in the
             study.

        Exclusion Criteria:

          -  Clinically significant disease with liver, renal, neurologic, respiratory, digestive,
             endocrine, hemato-oncology, urologic, cardiovascular, musculoskeletal, psychiatric
             system

          -  Subjects who have hypersensitivity for investigational products

          -  AST or ALT &gt; 2*ULN, r-GTP &gt; 1.5*ULN, Blood creatinine &gt; ULN (ULN, Upper Limit of
             Normal)

          -  SBP ≥ 140 mmHg or&lt; 90 mmHg, DBP ≥ 90 mmHg or &lt; 60 mmHg

          -  Subjects who were administered below medications within 30 days (barbiturates, drugs
             of induced or suppressive drug metabolizing enzyme, etc)

          -  Subjects who previously participated in other clinical trials or bioequivalence Test
             within 6 months

          -  Subjects with whole blood donation within 2 months or component blood donation within
             1 month or blood transfusion within 1 month prior to the first dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang-Hee Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials Center, Chungnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Center, Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

